Browse
Submit Data
Databases
API
Help

Dataset Information

7 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Can Chinese herbal topical wash relieve and/or prevent Oxaliplatin-induced peripheral neuropathy?

ABSTRACT: Interventions: Huo Xue Tong Luo Decoction will be provided as a whole concentrated granulated extract (45 g) (Salvia miltiorrhiza; Carthamus tinctorius L.;Paeonia veitchii; Ligusticum Siense; Angelica sinensis; Prunus persica; Rehmannia glutinosa; Polygonum bistort; Ginger) for topical use. Participants will dissolve daily sachets in a basin with 3 litres of warm water (approximately 37- 40 degrees) at home. Once the sachet is dissolved, participants will soak both hands in the basin for 20 minutes, and then soak both feet for 20 minutes once per day. Discard the solution when finished. Participants will have a total of 40 days using HXTLD treatments (5 days/per cycle x 8 cycles) over the six months of chemotherapy treatment. To ensure compliance, the participants have to return each cycle’s home diary and the empty sachets at each next visit. Participants will complete eight cycles’ home intervention records with one follow up home intervention record. Primary outcome(s): Change in the reduction of severity and/or delay onset of peripheral neuropathy by cold-evoked pain threshold measured by thermal quantitative sensory testing (QST)[before the fourth cycle of chemotherapy.] Study Design: Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Safety/efficacy

DISEASE(S): Chemotherapy-induced Peripheral Neuropathy,Neurological-other Neurological Disorders,Oesophageal Cancer,Cancer-stomach,Gastric Cancer,Gastrointestinal Cancer,Colorectal Cancer,Cancer-bowel-back Passage (rectum) Or Large Bowel (colon)

PROVIDER: 2465005 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

GR and Pol II interactions with regulatory elements in response to ultradian (pulsed) hormone stimulation [ChIP-seq]

Project description:We report changes in GR and Pol II binding profiles genome-wide upon treatment with corticosterone (Cort) for 20 minutes, treatment with Cort for 20 minutes followed by hormone withdrawal for 40 minutes, 60 minutes continuous stimulation with Cort, and 60 minutes continuous stimulation with Dexamethasone (Dex).

2015-02-12 | GSE61234 | GEO

Changes in DNaseI hypersensitivity upon ultradian (pulsed) hormone stimulation [Dnase-seq]

Project description:We report changes in DNaseI accessibility genome-wide upon treatment with corticosterone (Cort) for 20 minutes, treatment with Cort for 20 minutes followed by hormone withdrawal for 40 minutes, 60 minutes continuous stimulation with Cort, as well as Mock treatments for the aforementioned conditions.

2015-02-12 | GSE61235 | GEO

Heat-adaptive proteome in filling wheat grain

Project description:Wheat (T. aestivum L. Chinese Spring) plants were cultured in 25-cm buckets at a density of 16 plants per bucket in a greenhouse at a temperature of 15–30 °C. Plants were watered once a week, and artificial light was applied when there was fewer than 12 h of natural daylight. The flowering date of each spike was recorded when the first flower appeared on the spike. Comparable wheat plants were selected depending on the flowering time and growth status and were transferred into growth chambers 12 DAF for a three-day adaptation period to the growth chamber environment (24/17 °C, 14/10 h day/night cycle). Wheat plants were illuminated with a photosynthetic photon flux density of 360 µmol m˗2 s˗1 at canopy height, and relative humidity ranged from 40% to 70%. Half of the wheat plants (about 50 plants) were transferred to heated conditions (37/17 °C, 14/10 h day/night cycle, 40% to 70% humidity), while the others were maintained under the standard conditions described above as a control. After three day/night cycles, the heated samples were collected after the plants had been exposed to heat for 4 h, and the control samples from the unheated chambers were collected at the same time for and proteomic analyses. A minimum of 20 spikes were collected from each condition, immediately immersed in liquid nitrogen and stored at ˗80 °C until further analysis.

2018-08-29 | PXD010340 | Pride

Time-course of ischemia-reperfusion in a pig model

Project description:We have performed an unbiased, open-search analysis of the oxidative PTMs and quantitative multiplexed proteomics that take place in the pig ischemic heart tissue during the first 24h after I/R. We used 40 castrated male Large-White pigs weighing 30 to 40 kg. Closed-chest 40 min I/R was performed in 36 animals and they were sacrificed at 20 min, 40 min, 80 minutes, 2 hours, 6 hours, 12 hours and 24 hours after reperfusion after reperfusion (n = 4 per group). 4 animals were sacrificed with no intervention other than baseline cardiac magnetic resonance ( CMR), and served as controls. A new group of 4 animals were sacrificed at 120 minutes after artery occlusion without reperfusion, and other group of 4 animals were subjected to ischemic preconditioning prior to I/R and sacrificed at 24h. Myocardial tissue samples from ischemic area were collected for proteomics analysis.

2024-05-24 | PXD045771 | Pride

Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer

Project description:The main purpose of this clinical trial is to learn about the good and the bad effects of all trans retinoic acid (ATRA), atezolizumab and bevacizumab as a possible treatment for advanced colorectal patients. Participants will be treated with the following combination of these drugs: 1. ATRA will be given in a pill form to be taken twice a day at home for 7 days starting on day 1 of a cycle. 2. Atezolizumab will be given through a vein in arm or through mediport over 60-90 minutes every 2 weeks in the outpatient chemotherapy infusion centers at UTSW. 3. Bevacizumab will be given through a vein in arm or through mediport over 20-40 minutes every 2 weeks in the outpatient chemotherapy infusion centers at UTSW.

| 70824 | ecrin-mdr-crc

Effects of Cyclic Acute and Chronic Hypoxia on Expression Level of Metabolism Related Genes in a Pancreatic Cancer Cell Line

Project description:This work aims to characterize cycling hypoxia induced changes in metabolism related genes expression in pancreatic cancer cell line. PANC1were exposed to either 7 hours cycles of hypoxia every other day for 20 cycles cyclic acute hypoxia, or to 72 hours cycles of hypoxia once a week for 5 cycles cyclic chronic hypoxia. Gene expression changes were profiled using RT PCR and compared to cells under normoxia. Western blotting analysis confirmed upregulation of hypoxia inducible factor 1 α, glucose 6 phosphate isomerase gene, and ribokinase gene. Genes encoding glycolysis enzymes were upregulated under cyclic acute more than chronic hypoxia including hexokinase2 and phosphoglycerate kinase1. Genes encoding pentose phosphate pathway enzymes transketolase and transaldolase were upregulated similarly. Genes encoding pyruvate dehydrogenases that block pyruvate flow to TCA cycle were significantly upregulated. Exposure of PANC1 cells to acute hypoxia results in upregulation of genes that shift cells metabolism toward glycolysis and pentose phosphate pathways in adaptation to hypoxic stress

2022-06-28 | GSE207065 | GEO

Genetic and pharmacological evidence for kinetic competition between alternative poly(A) sites in yeast - cordycepin treatment

Project description:PAT-seq approach was used to determine changes to 3'UTR length in yeast upon addition of 20µg/ml cordycepin (3'deoxyadenosine) for 0, 5, 10, 20 or 40 minutes

2021-06-25 | GSE160537 | GEO

Halobacterium NRC-1, H2O2 Stress Response

Project description:50mM H2O2 was added to mid-log phase Halobacterium NRC-1 cultures. After constant stress of H2O2 for 30 minutes, cultures were spun down and pellets were resuspended in same volume of GN101 media. Samples for RNA preparation were collected during recovery time points at 0, 10, 20, 30, 40, 60 and 120 minutes. Keywords: stress response

2008-01-03 | GSE7610 | GEO

Time course of glycine addition or withdrawal

Project description:+Gly 20, 40, 80: Cells were grown to early log phase (OD600 ~ 0.2) at 30oC in 1 liter of minimal B medium (Cherest, H., and Surdin-Kerjan, Y. (1992) Genetics 130, 51-58) and t=0 time point samples were harvested (250 ml). The remainder of the medium was supplemented with 10 mM glycine incubated at 30oC and samples (250 ml) harvested at 20, 40 and 80 minutes. All cells were harvested by rapid centrifugation at room temperature then flash frozen in liquid nitrogen. -Gly 20, 40, 80: Cells were grown to early log phase (OD600 ~ 0.2) at 30oC in 1 liter of minimal B medium (Cherest, H., and Surdin-Kerjan, Y. (1992) Genetics 130, 51-58) supplemented with 10 mM glycine and t=0 time point samples were harvested (250 ml). The remainder of the medium was filtered and the cells were rapidly resuspended in 750 ml of pre-warmed B minimal medium, incubated at 30oC and samples (250 ml) harvested at 20, 40 and 80 minutes. All cells were harvested by rapid centrifugation at room temperature then flash frozen in liquid nitrogen. Keywords: time-course

2004-07-17 | GSE1554 | GEO

Preventing Nerve Damage Induced by Chemotherapy

Project description:Interventions: Calcium 1 gm/10 mL and magnesium 1gm/2mL administered simultaneously , or placebo of 5% Dextrose 12mL intravenous infusion, given over 20 minutes, prior to and after chemotherapy on Day1 Cycle 1 and then 21 days later on Day 1 Cycle 2 Primary outcome(s): Intact Oxaliplatin parameters. A HPLC-tandem mass spectrometry method was developed and validated for the quantitation of intact oxaliplatin in human plasma[13 samples during Day 1 of each of Cycle 1 and Cycle 2 at pre treatment and 20, 40, 60, 90mins during oxaliplatin infusion, end of infusion and 5, 10, 20, 30, 60, 120, 180 minutes after the end of oxaliplatin infusion] Study Design: Purpose: Prevention; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Crossover;Type of endpoint: Pharmacokinetics / pharmacodynamics

| 2457191 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data